News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
6 hrs ago | Wall St. Cheat Sheet
The company manages its operations through five segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health and Consumer Healthcare, and Nutrition.
Trending on the Topix Network
The Wall Street Bull Market Express is leaving the station and you have two months, maybe three to run down the platform, take the leap, and latch on to the caboose.
Merck's antifungal agent is also marketed as NOXAFIL delayed-release tablets and NOXAFIL oral suspension.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application for Eliquis for the prophylaxis of deep vein thrombosis , which may lead to pulmonary embolism , in patients who have undergone hip or knee replacement surgery.
U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.
In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer , and raised the price target from $34.00 to $36.00.
"Our recent efforts, including the addition of capital to the balance sheet, have put the Company in a solid position to achieve some key milestones and continue building value for our stockholders."
The Dow Jones industrial average fell 231.19 points to 16,108.89, a loss of 1.41 percent.
Pfizer Inc., the world's biggest drugmaker, faces competition to its $3 billion arthritis pill Celebrex in May after a federal judge invalidated a patent that could have delayed generic versions of the medicine.
NEARLY NINE years have elapsed since the US Supreme Court, in one of its most notorious rulings , decided that seven homeowners in the Fort Trumbull neighborhood of New London, Conn., had no property rights which City Hall was bound to respect.
Yesterday was another deadly, dull day on Wall Street, with the S&P 500 Index advancing all of 0.03%, but compared with the excitement that occurred exactly 13 years earlier, sometimes it's better to be boring.
Pfizer Inc. said it will appeal a court ruling that invalidated a patent covering the method of treating osteoarthritis with the active ingredient in Celebrex.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer's Oncology leadership on Sunday, April 6, 2014 at 1:30 p.m. Pacific Daylight Time, in connection with the presentation of the final results of the PALOMA-1 Phase 2 trial for palbociclib at the American Association for Cancer Research ... (more)
Shares of Pfizer were the target of some unusual options trading activity on Wednesday.
Trading of Pfizer Inc. stock was halted briefly in Wednesday trading on news that a court has invalidated a patent for one of its top-selling medicines, potentially opening the door for cheaper generic versions 18 months sooner than expected.
Pharmaceutical giant Pfizer Inc. said Wednesday afternoon it will appeal a ruling that invalidated a key patent extension related to Celebrex.